Harvard--MIT research program in short-lived radiopharmaceuticals

Technical Report · Fri Mar 01 04:00:00 EST 1991

OSTI ID:6000562

This report describes progress on five projects. The first project showed a 1000 fold concentration of the cationic complex {sup 99m}Tc (MIBI) in heart cell mitochondria vs heart cell cytoplasm, as determined by high resolution electron probe microanalysis. Additional technetium-99m based complexes are being developed and tested. The second project involves evaluating technetium acetylacteonates as potential indicators of cerebral blood flow. An intermediate in the synthesis of a technetium porphyrin complex has been synthesized; an oxotechnetium(V)-2,4-pentanedione complex has been prepared and is currently being characterized. The third project involves using radio labelled antibodies for diagnosis and treatment of cancer. An early discovery was that chloramine-T based iodination protocols resulted in a reversal of the charge on mouse lgGs. Immunoperoxidase-labelled monoclonal antibody MOv 18 was shown to bind specifically to the most frequent ovarian aderon carcinomas, and not to healthy tissue, making this antibody a good candidate for immunotherapy or immunodetection. Work on a specific immunotherapy protocol suffered a setback when one reagent, a {sup 125}I-biotin complex, proved to be unstable in vivo. The fourth project involves labelling antibodies with positron emitting radionuclides. Radiofluorination was accomplished through reductive alkylation of {sup 18}F-aldehyde, or pentafluorophenyl esters. Radioiodination was accomplished using alkyl-tin derivation exchange. The fifth project examined antibody modification for use in radioimmune imaging. Technetium-99m-labelled lgG was shown to be biologically equivalent to Indium-III-labelled lgG for imaging focal sites of inflamation. Also, Indium III labelling of small bioactive peptides was examined as a means of imaging important physiological processes. 44 refs., 2 figs.

• Research Organization: Massachusetts Inst. of Tech., Cambridge, MA (USA)
• Sponsoring Organization: DOE; USDOE, Washington, DC (USA)
• DOE Contract Number: FG02-86ER60460
• OSTI ID: 6000562
• Report Number(s): DOE/ER/60460-10; ON: DE91009050
• Country of Publication: United States
• Language: English

Related Subjects

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY
400703 -- Radiochemistry & Nuclear Chemistry-- Radioisotope Production
550201 -- Biochemistry-- Tracer Techniques
550601* -- Medicine-- Unsealed Radionuclides in Diagnostics
550604 -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
59 BASIC BIOLOGICAL SCIENCES
62 RADIOLOGY AND NUCLEAR MEDICINE
ANIMAL CELLS
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
BIOLOGICAL FUNCTIONS
BIOMEDICAL RADIOGRAPHY
BLOOD FLOW
BLOOD-BRAIN BARRIER
CARBOXYLIC ACIDS
CELL CONSTITUENTS
CHEMICAL REACTIONS
COMPLEXES
COUNTING TECHNIQUES
CYTOPLASM
DAYS LIVING RADIOISOTOPES
DIAGNOSTIC TECHNIQUES
DISEASES
DISTRIBUTION
DOCUMENT TYPES
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
FLUORINE 18
FLUORINE ISOTOPES
FUNCTIONS
HALOGENATION
HETEROCYCLIC ACIDS
HETEROCYCLIC COMPOUNDS
HOURS LIVING RADIOISOTOPES
INDIUM 111
INDIUM ISOTOPES
INFLAMMATION
INTERMEDIATE MASS NUCLEI
IODINATION
IODINE 125
IODINE 131
IODINE COMPLEXES
IODINE ISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
LABELLED COMPOUNDS
LABELLING
LIGHT NUCLEI
MEDICINE
MINUTES LIVING RADIOISOTOPES
MITOCHONDRIA
MONOCLONAL ANTIBODIES
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ODD-ODD NUCLEI
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANOIDS
PATHOLOGICAL CHANGES
PEPTIDES
PORPHYRINS
PROGRESS REPORT
PROTEINS
RADIOIMMUNODETECTION
RADIOIMMUNOSCINTIGRAPHY
RADIOISOTOPE SCANNING
RADIOISOTOPES
RADIOLOGY
RADIOPHARMACEUTICALS
RADIOTHERAPY
SCINTISCANNING
SUBCELLULAR DISTRIBUTION
SYMPTOMS
SYNTHESIS
TECHNETIUM 99
TECHNETIUM COMPLEXES
TECHNETIUM ISOTOPES
THERAPY
TRACER TECHNIQUES
TRANSITION ELEMENT COMPLEXES
TUMOR CELLS
YEARS LIVING RADIOISOTOPES